THE WOOF OF WALL STREET

[Jugas]

ARGS near 52-week lows, great 8-k out last night missed by most, company fully funded through the rest of 2018:

https://backend.otcmarkets.com/otcapi/company/sec-filings/12610435/content/html

Item 8.01. Other Events.



Argos Therapeutics, Inc. (the “Company”) is providing certain information related to its cash and cash equivalents and cash runway as an update to the information provided in the Company’s previous periodic filings. The Company estimates that its cash and cash equivalents as of December 31, 2017 were approximately $15.2 million. The Company expects that its current cash and cash equivalents, including the approximately $4.6 million in net proceeds that the Company has raised from the sale of its common stock in its at-the-market facility in the first quarter of 2018 as of March 2, 2018 and the previously announced $1.5 million equity investment by Lummy (Hong Kong) Ltd., that the Company expects to receive upon the closing of the investment in March 2018, will be sufficient to fund its operations through the end of 2018. The Company’s estimate of its cash and cash equivalents as of December 31, 2017 is an estimate prepared by management in good faith based upon internal reporting and expectations. This estimate is preliminary and unaudited, and may be revised as a result of management's further review of the Company’s financial results. The Company’s auditors have not completed the normal annual audit procedures as of and for the period ended December 31, 2017, and there can be no assurance that the final results for this period will not differ from this estimate.